Last reviewed · How we verify
KAI-9803
At a glance
| Generic name | KAI-9803 |
|---|---|
| Sponsor | KAI Pharmaceuticals |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack (PHASE1, PHASE2)
- Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack] (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KAI-9803 CI brief — competitive landscape report
- KAI-9803 updates RSS · CI watch RSS
- KAI Pharmaceuticals portfolio CI